Does Kevzara Work for Rheumatoid Arthritis?
Kevzara (sarilumab) is FDA-approved to treat moderate to severe rheumatoid arthritis (RA) in adults who have not responded well to one or more tumor necrosis factor (TNF) inhibitors. Clinical trials show it reduces signs and symptoms of RA, inhibits joint damage progression, and improves physical function. In the MOBILITY trial, 58% of patients on Kevzara 200 mg plus methotrexate achieved ACR20 response (20% improvement in RA symptoms) at week 24, compared to 44% on placebo plus methotrexate.[1][2]
How Does Kevzara Compare to Other RA Drugs?
Kevzara, an IL-6 receptor inhibitor, matches or exceeds TNF inhibitors like Humira or Enbrel in head-to-head trials for patients with prior TNF failure. The MONARCH trial found Kevzara superior to adalimumab on ACR20 (52% vs. 47%) and low disease activity measures.[1] Unlike JAK inhibitors (e.g., Xeljanz), it targets a different pathway, potentially suiting patients with specific inflammatory profiles. Real-world data from registries like Corrona confirm sustained efficacy over 2-5 years.[2]
What Do Phase 3 Trial Results Show?
Two pivotal trials support approval:
- MOBILITY: 1,197 patients; Kevzara + methotrexate reduced radiographic joint damage (modified Sharp score change: 0.90 vs. 2.78 placebo) and hit ACR50 in 31-37% vs. 18%.[1]
- TARGET: 546 TNF-experienced patients; ACR20 rates hit 61% (200 mg) vs. 40% active comparator (non-biologic DMARDs).[1]
Responses often appear by week 4, with peak effects at 12-24 weeks. Long-term extensions show 40-50% maintaining low disease activity at 5 years.[2]
Who Responds Best and When Does It Fail?
Best for TNF-inadequate responders; about 50-60% achieve significant symptom relief. Factors like high baseline CRP levels predict stronger responses. Non-responders (20-30%) may switch to other biologics. Loss of efficacy occurs in 10-15% over time due to anti-drug antibodies (5-10% incidence).[1][2]
What Side Effects Limit Its Use?
Common issues include infections (e.g., upper respiratory, 5-10%), neutropenia (10-20%), elevated liver enzymes, and injection-site reactions. Serious risks: serious infections (4.4/100 patient-years), GI perforations (rare, higher with steroids/NSAIDs), and malignancy signals in trials (similar to placebo). Black box warning for infections; monitor lipids and blood counts.[1][2] Patient forums report fatigue and headaches as frequent complaints.
Is Kevzara Still Under Patent Protection?
Kevzara's key composition-of-matter patent (US 7,582,298) expires in 2025, with formulation patents extending to 2031. No major challenges listed yet on DrugPatentWatch; biosimilars unlikely before 2032 due to exclusivities.[3]
[1]: FDA Kevzara Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761924lbl.pdf
[2]: Sanofi/Regeneron Clinical Data Summary - https://www.kevzara.com/content/dam/websites/hcp-kevzara/hcp/pdf/hcp-efficacy.pdf
[3]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/KEVZARA